目的:对比研究FLOT方案与FOLFOX方案治疗中晚期胃癌(GC)的近远期疗效及对血清肿瘤标志物和NRP-2的影响。方法:选入我院2020年3月~2022年2月收治的82例中晚期GC患者,根据化疗方法不同分为FLOT组和FOLFOX组,各41例。比较两组的近远期疗效...目的:对比研究FLOT方案与FOLFOX方案治疗中晚期胃癌(GC)的近远期疗效及对血清肿瘤标志物和NRP-2的影响。方法:选入我院2020年3月~2022年2月收治的82例中晚期GC患者,根据化疗方法不同分为FLOT组和FOLFOX组,各41例。比较两组的近远期疗效、血清肿瘤标志物和NRP-2水平;随访至2023年11月,记录两组患者生存状态并绘制Kaplan-Meier生存曲线。结果:FLOT组客观有效率显著高于FOLFOX组(85.37%vs.65.85%,P<0.05)。FLOT组治疗后血清癌胚抗原[(12.77±1.85)ng/m L vs.(20.69±2.58)ng/mL]、糖类抗原19-9[(20.46±5.20)U/m L vs.(29.41±8.04)U/m L]、糖类抗原125[(14.90±5.61)U/m L vs.(20.72±6.23)ng/mL]和NRP-2[(13.01±2.11)ng/mL vs.(15.23±2.25)ng/mL]水平均显著低于FOLFOX组,PFS[12.900(95%CI:12.183~13.617)个月vs.9.600(95%CI:8.471~10.729)个月]和OS[28.103(95%CI:25.209~30.996)个月vs.20.799(95%CI:18.482~23.115)个月]显著长于FOLFOX组(P<0.05)。两组疾病控制率和毒副反应发生率无显著差异(P>0.05)。结论:FLOT方案和FOLFOX方案均是中晚期GC的有效化疗方案,安全性一致,但前者在提高客观有效率、降低血清肿瘤标志物和NRP-2水平、延长生存期方面更具优势。展开更多
Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be ...Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer（NSCLC） and their clinical significance by observing patient prognosis. Methods： VEGFR2 and NRP-1 were assessed by immunohistochemistry（IHC） in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor（KDR） and NRP-1 copy number gain（CNG） was assessed by fluorescence in situ hybridization（FISH）. The distributions of overall survival（OS） and progression-free survival（PFS） were estimated using the Kaplan-Meier method and compared between groups by log-rank test.Results： Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG（＋） were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue（χ2=11.22, P=0.001; χ2=9.82, P=0.001, respectively）; similar results were obtained using CNGs（χ2=4.39, P=0.036; χ2=3.95, P=0.046, respectively）. Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status（P〈0.05）, but not age, gender or pathology type（P〉0.05）. VEGFR2 showed a strong correlation with NRP-1（Rs=0.68, P=0.00）; similar results were observed with KDR and NRP-1 CNG（Rs=0.32, P=0.04）. Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression（P〈0.05）. Conclusions： According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis（P〈0.05 for OS and PFS）. This information will be beneficial for clinical antiangiogenic treatment in NSCLC.展开更多
文摘目的:对比研究FLOT方案与FOLFOX方案治疗中晚期胃癌(GC)的近远期疗效及对血清肿瘤标志物和NRP-2的影响。方法:选入我院2020年3月~2022年2月收治的82例中晚期GC患者,根据化疗方法不同分为FLOT组和FOLFOX组,各41例。比较两组的近远期疗效、血清肿瘤标志物和NRP-2水平;随访至2023年11月,记录两组患者生存状态并绘制Kaplan-Meier生存曲线。结果:FLOT组客观有效率显著高于FOLFOX组(85.37%vs.65.85%,P<0.05)。FLOT组治疗后血清癌胚抗原[(12.77±1.85)ng/m L vs.(20.69±2.58)ng/mL]、糖类抗原19-9[(20.46±5.20)U/m L vs.(29.41±8.04)U/m L]、糖类抗原125[(14.90±5.61)U/m L vs.(20.72±6.23)ng/mL]和NRP-2[(13.01±2.11)ng/mL vs.(15.23±2.25)ng/mL]水平均显著低于FOLFOX组,PFS[12.900(95%CI:12.183~13.617)个月vs.9.600(95%CI:8.471~10.729)个月]和OS[28.103(95%CI:25.209~30.996)个月vs.20.799(95%CI:18.482~23.115)个月]显著长于FOLFOX组(P<0.05)。两组疾病控制率和毒副反应发生率无显著差异(P>0.05)。结论:FLOT方案和FOLFOX方案均是中晚期GC的有效化疗方案,安全性一致,但前者在提高客观有效率、降低血清肿瘤标志物和NRP-2水平、延长生存期方面更具优势。
基金supported by National Natural Science Foundation of China [81472792]Ministry of Health of China (W201210)Jiangsu Natural Science Foundation of China (BK2012661)
文摘Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer（NSCLC） and their clinical significance by observing patient prognosis. Methods： VEGFR2 and NRP-1 were assessed by immunohistochemistry（IHC） in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor（KDR） and NRP-1 copy number gain（CNG） was assessed by fluorescence in situ hybridization（FISH）. The distributions of overall survival（OS） and progression-free survival（PFS） were estimated using the Kaplan-Meier method and compared between groups by log-rank test.Results： Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG（＋） were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue（χ2=11.22, P=0.001; χ2=9.82, P=0.001, respectively）; similar results were obtained using CNGs（χ2=4.39, P=0.036; χ2=3.95, P=0.046, respectively）. Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status（P〈0.05）, but not age, gender or pathology type（P〉0.05）. VEGFR2 showed a strong correlation with NRP-1（Rs=0.68, P=0.00）; similar results were observed with KDR and NRP-1 CNG（Rs=0.32, P=0.04）. Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression（P〈0.05）. Conclusions： According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis（P〈0.05 for OS and PFS）. This information will be beneficial for clinical antiangiogenic treatment in NSCLC.
